Previous 10 |
Exscientia plc (EXAI) Q3 2021 Earnings Conference Call November 18, 2021 08:30 ET Company Participants Sara Sherman - Vice President, Investor Relations Andrew Hopkins - Chief Executive Officer Ben Taylor - Chief Financial Officer and Chief Strategy Officer Dave Hallett - Chief Operations Off...
Exscientia (NASDAQ:EXAI): Q3 GAAP EPS of -£0.06. Revenue of £17.6M (+1660.0% Y/Y) Press Release For further details see: Exscientia reports Q3 results
Exscientia (Nasdaq: EXAI): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211117006300/en/ (Graphic: Business Wire) Recent advancements in the Company’s pipeline, collaborations and operations as we...
Company to host conference call and webcast on November 18, 2021 at 1:30 p.m. GMT / 8:30 a.m. ET Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, wi...
Study shows benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancers 54% of patients demonstrated a clinical benefit of more than 1.3-fold enhanced progression-fr...
Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the closing of its previously-announced upsized initial public offering in the United State...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to com...
— State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost — Exscientia ...